title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects With Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid Treatment

acronym: AIM-PMR

summary:
Polymyalgia rheumatica (PMR) is an inflammatory disease causing shoulder, hip, and neck pain and stiffness, in adults aged 50 years or older. This study evaluates how safe and effective ABBV-154 is in participants with glucocorticoid-dependent PMR. Adverse events and change in disease activity will be assessed.

ABBV-154 is an investigational drug being evaluated for the treatment of PMR. Participants will be randomized into 1 of 4 treatment groups or arms, each arm receiving a different treatment. There is a 2 in 5 chance that a participant will be assigned to placebo. Around 200 participants, 50 to 80 years of age, with PMR will be enrolled in the study at approximately 95 sites worldwide.

The study is compromised of a 52 week double-blind, placebo-controlled period and a follow-up visit 70 days after the last dose of the study drug. All participants will receive a glucocorticoid taper along with the assigned dose of ABBV-154 or placebo, subcutaneously (SC) every other week (eow).

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

ipd_sharing_description: AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

lead_sponsor: AbbVie

location_country:
Italy
Austria
United States
Netherlands
Germany
France
Japan
Poland
Hungary
Australia
New Zealand
Spain
Canada
United Kingdom
Korea, Republic of

location_facility: CMED Rehabilitacios es Diagnosztikai Kozpont /ID# 230065

location_facility: Hans Richard Barthel, M.D., Inc /ID# 231902

location_facility: Maastricht Universitair Medisch Centrum /ID# 227779

location_facility: Tokyo Medical And Dental University Hospital /ID# 232206

location_facility: Hospital Universitario Canarias /ID# 229451

location_facility: National Hospital Organization Shimoshizu National Hospital /ID# 230500

location_facility: Centre de Recherche Musculo-Squelettique /ID# 228392

location_facility: Charite Universitaetsmedizin Berlin - Campus Mitte /ID# 228661

location_facility: A.O.U. Citta della Salute e della Scienza di Torino /ID# 229080

location_facility: The Royal Wolverhampton NHS Trust /ID# 230302

location_facility: Niepubliczny Zaklad Opieki Zdrowotnej Biogenes Sp. z o.o /ID# 228357

location_facility: Matsuyama Red Cross Hospital /ID# 230458

location_facility: North West Anglia NHS Foundation Trust /ID# 230866

location_facility: Articularis Healthcare Group, Inc d/b/a Low Country Rheumatology /ID# 228860

location_facility: Csongrad-Csanad Megyei Dr. Bugyi Istvan Korhaz /ID# 229793

location_facility: West Tennessee Research Institute /ID# 228854

location_facility: The Royal Free London NHS Foundation Trust /ID# 231707

location_facility: Szpital Uniwersytecki nr 2 im. dr. Jana Biziela /ID# 228353

location_facility: Paramount Medical Research Con /ID# 228839

location_facility: ASL 3 Genovese - Ospedale la Colletta /ID# 229282

location_facility: Revival Research Institute LLC - Sterling Heights /ID# 232218

location_facility: Dartmouth-Hitchcock Medical Center /ID# 229557

location_facility: Obudai Egeszsegugyi Centrum Kft. Zalaegerszeg /ID# 229759

location_facility: Arthritis and Rheumatism Associates /ID# 232089

location_facility: Rheumatology Consultants - Clinical Research /ID# 232137

location_facility: Bekes Megyei Kozponti Korhaz Pandy Kalman Tagkorhaz /ID# 229758

location_facility: Care Access Research, Huntington Beach /ID# 228677

location_facility: AI Centrum Medyczne Sp. z o.o. sp.k. /ID# 228951

location_facility: Norfolk and Norwich University Hospitals NHS Foundation Trust /ID# 231966

location_facility: CHRU Tours - Hopital Trousseau /ID# 228349

location_facility: Hanyang University Seoul Hospital /ID# 228719

location_facility: International Medical Research - Daytona /ID# 228765

location_facility: Kyushu University Beppu Hospital /ID# 232250

location_facility: Arthritis & Osteo Medical Ctr /ID# 228680

location_facility: Hospital Clinico Universitario San Carlos /ID# 229296

location_facility: Vital Medical Center Orvosi es Fogaszati Kozpont (Vital Medicina Kft.) /ID# 229674

location_facility: CHU Montpellier - Hôpital Lapeyronie /ID# 228347

location_facility: Azienda Ospedaliero-Universitaria di Modena /ID# 228825

location_facility: Rheuma-Zentrum Wien-Oberlaa GmbH /ID# 229436

location_facility: MVZ Rheumatologie und Autoimmunmedizin Hamburg GmbH /ID# 228658

location_facility: Universitair Medisch Centrum Groningen /ID# 227727

location_facility: Azienda Ospedaliera Universitaria Friuli Centrale/Presidio Ospedaliero Universit /ID# 228815

location_facility: Hospital for Special Surgery /ID# 228577

location_facility: Wellington Regional Hospital /ID# 229490

location_facility: Hopital de la Cavale Blanche /ID# 228348

location_facility: Rheumatology Care Center PLLC /ID# 232306

location_facility: Debreceni Egyetem Klinikai Kozpont /ID# 241674

location_facility: Kyungpook National University Hospital /ID# 228716

location_facility: The Queen Elizabeth Hospital /ID# 229049

location_facility: Rheumatology Associates of South Florida (RASF) - Clinical Research /ID# 232238

location_facility: Obudai Egeszsegugyi Centrum Kft. /ID# 231121

location_facility: CISSSBSL -Hopital regional de Rimouski /ID# 228394

location_facility: Providence Medical Foundation /ID# 228681

location_facility: Rheumatology Research Associates /ID# 230363

location_facility: Nova Reuma Domyslawska I Rusilowicz - Spolka Partnerska Lekarza Reumatologa I Fi /Id# 228466

location_facility: Manchester University NHS Foundation Trust /ID# 230886

location_facility: Ortopedyczno-Rehabilitacyjny Szpital Kliniczny im. Wiktora Degi /ID# 228314

location_facility: Hospital Unversitario Marques de Valdecilla /ID# 229297

location_facility: Hospital General Universitario Gregorio Maranon /ID# 229302

location_facility: Timaru Medical Specialists Ltd /ID# 229098

location_facility: Japanese Red Cross Okayama Hospital /ID# 230857

location_facility: Inland Rheum & Osteo Med Grp /ID# 228679

location_facility: Toyama Prefectural Central Hospital /ID# 230616

location_facility: Pest Megyei Flor Ferenc Korhaz /ID# 229676

location_facility: Four Rivers Clinical Research /ID# 228858

location_facility: Clinical Research Source, Inc. /ID# 231903


design_allocation: Randomized

intervention_type: Drug

status: Recruiting

study_start_date_type: Actual

study_type: Interventional

enrollment_type: Anticipated

primary_purpose: Treatment

location_country:
United States
Canada
France
Japan

location_facility: HCL - Hopital Edouard Herriot /ID# 228194

location_facility: CHU Toulouse - Hopital Larrey /ID# 228196

location_facility: Oregon Medical Res Center PC /ID# 228073

location_facility: Tokyo Medical University Hospital /ID# 230288

location_facility: Dr. Chih-ho Hong Medical Inc. /ID# 228403

location_facility: International Clinical Research - Tennessee LLC /ID# 228059

location_facility: Wiseman Dermatology Research /ID# 228410

location_facility: Essential Medical Research, LLC /ID# 228074

location_facility: Oregon Dermatology and Research Center /ID# 228007

location_facility: Yamanashi Prefectural Central Hospital /ID# 229441

location_facility: Michigan Center for Research Company /ID# 228054

location_facility: University of California Irvine /ID# 229390

location_facility: Nagoya City University Hospital /ID# 228725

location_facility: Medical University of South Carolina /ID# 228067

location_facility: University of Texas Health Science Center at Houston /ID# 229399

location_facility: Virginia Clinical Research, Inc. /ID# 228050

location_facility: Centre de recheche dermatologique du Quebec Metropolitain /ID# 228388

location_facility: Chu de Nice-Hopital L'Archet Ii /Id# 228192

location_facility: Remington-Davis Clinical Research /ID# 229401

location_facility: Nippon Medical School Hospital /ID# 230361

location_facility: Yamagata University Hospital /ID# 230362

ipd_sharing: Yes

study_completion_date_type: Anticipated

type: EudraCT Number

source: euctr

title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Safety and Efficacy of Upadacitinib in Subjects With Non-Segmental Vitiligo

summary:
Vitiligo is a common chronic autoimmune disease that causes the body's immune system to attack its own pigment producing skin cells. This study is to evaluate how safe and effective upadacitinib is in participants with non-segmental vitiligo. Adverse effects and change in disease activity will be assessed.

Upadacitinib is being evaluated for the treatment of non-segmental vitiligo. The study will enroll approximately 160 participants aged 18-65 with non-segmental vitiligo in 5 treatment arms across 35 sites worldwide.

Participants will either receive study drug vs placebo oral tablets once daily (QD) for 24 weeks (Period A). In Period B (up to 52 weeks), participants who received placebo during the first 24 weeks will switch to study drug. Participants who received study drug during the first 24 weeks, will continue to receive study drug.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

lead_sponsor_type: industriel

status_simplified: Ongoing


type: Other Identifier

title: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Nipocalimab in Adult Participants With Active Lupus Nephritis

summary: The purpose of this study is to evaluate the efficacy of nipocalimab versus placebo in participants with active Lupus Nephritis (LN).

study_start_date_type: Anticipated

status: Not yet recruiting

ipd_sharing_description: The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

lead_sponsor: Janssen Research & Development, LLC

location_country:
Italy
United States
South Africa
Hong Kong
France
Israel
Portugal
Germany
Korea, Republic of
Taiwan
Ukraine

location_facility: Municipal Non-Profit Enterprise of Kharkiv Regional Council 'Regional Clinical Hospital'

location_facility: Arthritis & Osteoporosis Medical Center - La Palma

location_facility: Severance Hospital, Yonsei University Health System

location_facility: Communal Noncommercial Enterprise 'Cherkasy Regional Hospital of Cherkasy Regional Council'

location_facility: Medical Center 'Ok Clinic' of International Institute of Clinical Research LLC

location_facility: Integral Rheumatology & Immunology Specialists

location_facility: Arizona Arthritis & Rheumatology Research, PLLC

location_facility: Municipal Non-Profit Enterprise 'Chernihiv Regional Hospital' of Chernihiv Regional Council

location_facility: Kyiv Railway Clinical Hospital #2 Of Branch 'Health Center' Of The Company 'Ukrainian Railway'

location_facility: ME 'Poltava Regional Clinical Hospital named after M.V. Sklifosovsky of Poltava Regional Consuil'

location_facility: Azienda Ospedaliera Universitaria Federico II

location_facility: Communal Nonprofit Enterprise of Lviv Regional Council 'Lviv Regional Clinical Hospital'

location_facility: Municipal Non-commercial Enterprise 'Ternopil University Hospital' of Ternopil Regional Council

location_facility: Municipal Non-profit Enterprise 'Odesa Regional Clinical Hospital' Odesa Regional Council

location_facility: Arizona Arthritis and Rheumatology Research, PLLC

location_facility: Ce 'Dnipropetrovsk Regional Clinical Hospital N.A. Mechnikov' of Dnipropetrovsk Rc

location_facility: MNCE Zakarpatska Regional Clinical Hospital named after A Novak of Zakarpatska Regional Council

location_facility: Medical Center of 'Institute of Rheumatology', LLC

location_facility: Valerius Medical Group & Research Center

location_facility: Municipal Enterprise 'Kryvyi Rih City Clinical Hospital #2' Kryvyi Rih City Council

intervention_type: Other


title: A Phase 1B/2 Randomized, Multicenter, Open-Label Study Of Iberdomide (CC-220) In Combination With Polatuzumab Vedotin Plus Rituximab Or Tafasitamab Or Rituximab Plus Chemotherapy For Subjects With Relapsed Or Refractory Aggressive B-Cell Lymphoma

summary: This is a Phase 1b/2 randomized study of Iberdomide (CC-220) added to 3 different combination regimens (polatuzumab vedotin plus rituximab (Cohort A), tafasitamab (Cohort B), rituximab plus gemcitabine and platinum-based chemotherapy (Cohort C)) for participants with relapsed or refractory aggressive B-cell lymphoma (R/R a-BCL). All 3 cohorts will be open for enrollment at study start. Part 1 (dose escalation) will be followed by Part 2 (dose expansion), in which participants will be randomized to one of three cohorts, with CC-220 at the recommended Phase 2 Dose in combination with the Cohorts A, B and C treatment that is compared to their individual standard of care regimen.

status: Withdrawn

design_allocation: Non-Randomized

enrollment_type: Actual

ipd_sharing_description:
Information relating to our policy on data sharing and the process for requesting data can be found at the following link:

https://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/

lead_sponsor: Celgene

location_country:
Austria
France
Belgium
Spain
United States
United Kingdom
Korea, Republic of
Taiwan

location_facility: Complejo Asistencial Universitario de Salamanca - H. Clinico

location_facility: Hospital Universitario Germans Trias i Pujol

location_facility: University of Michigan Comprehensive Cancer Center

location_facility: Hospital Universitario Virgen del Rocio - PPDS

location_facility: University Hospital Southampton NHS Foundation Trust - Southampton General Hospital

location_facility: Nottingham University Hospitals NHS Trust

status_simplified: Unknown


lead_sponsor: Kite, A Gilead Company

location_country:
Germany
United States
France
Netherlands

location_facility: Cleveland Clinic - Taussig Cancer Institute

location_facility: University California Los Angeles (UCLA)

ipd_sharing: No

title: A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects With Relapsed/Refractory Mantle Cell Lymphoma

summary: The primary objective is to evaluate the efficacy of brexucabtagene autoleucel (KTE-X19) in participants with relapsed/refractory (r/r) mantle cell lymphoma (MCL) in Cohort 3 of this study.


title: Renal Mode of Action of Semaglutide in Patients With Type 2 Diabetes and Chronic Kidney Disease

acronym: REMODEL

summary:
We are doing this study to learn more about how semaglutide may help fight chronic kidney disease in people with type 2 diabetes. We are doing this by looking into how semaglutide works in the kidneys.

Participants will either get semaglutide or placebo (a 'dummy' medicine) - which treatment participants get is decided by chance.

Semaglutide is a medicine doctors can prescribe in some countries for the treatment of type 2 diabetes.

Participants will get the study medicine in a pen. Participants will use the pen to inject the medicine into the skin once a week.

The study will last for about 1 year. Participants will have 11 visits to the clinic, and 2 phone visits. Some of the visits could be in different locations.

Study staff will take blood samples at most of these visits. At 9 visits, participants will be asked to bring a sample of their first morning urine. At 4 of the visits participants will have to bring urine that they have collected over the last 24 hours.

The study includes magnetic resonance imaging (MRI) scans of participants' kidneys which is a test that shows a detailed picture of organs and other parts inside the body. The scan will last for 30 minutes, and is free of radiation.

ipd_sharing_description: According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

lead_sponsor: Novo Nordisk A/S

location_country:
Italy
South Africa
France
Poland
Spain
United States


title: A Phase 1b Study of BMS-986158 Monotherapy and in Combination With Either Ruxolitinib or Fedratinib in Participants With DIPSS-Intermediate or High Risk Myelofibrosis

summary: The purpose of this study is to assess the safety, tolerability, and efficacy of BMS-986158 alone and in combination with either Ruxolitinib or Fedratinib in participants with Dynamic International Prognostic Scoring System (DIPSS)-intermediate or high risk blood cancer. Part 1 consists of BMS-986158 in combination with either Ruxolitinib or Fedratinib and Part 2 consists of BMS-986158 in combination with either Ruxolitinib or Fedratinib and BMS-986158 alone.

lead_sponsor: Bristol-Myers Squibb

location_country:
Italy
France
Israel
Australia
Spain
United States

location_facility: Hôpital Saint-Louis-Centre d'Investigations Cliniques


title: A First in Human Study of the Menin-KMT2A (MLL1) Inhibitor JNJ-75276617 in Participants With Acute Leukemia

summary: The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2D[s]) of JNJ-75276617 in Part 1 (Dose Escalation) and to determine safety and tolerability at the RP2D(s) in Part 2 (Dose Expansion).

ipd_sharing_description:
The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency.

As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

location_country:
France
Australia
Spain
United States
United Kingdom

location_facility: Centre Hospitalier Universitaire (CHU) de Bordeaux Hopital HautLeveque Centre Francois Magendie

location_facility: Institut Universitaire du Cancer Toulouse Oncopole

location_facility: University of California Irvine Medical Center

location_facility: Guy's and St Thomas' NHS Foundation Trust


intervention_type: Biological

location_country:
Italy
Brazil
Chile
Mexico
Spain
Finland
France
Czechia
Poland
Romania
Ireland
Argentina
Russian Federation
New Zealand
Portugal
Turkey
United States

location_facility: Centrum Onkologii im. Prof. F. Lukaszczyka

location_facility: IOV - Istituto Oncologico Veneto - IRCCS

location_facility: Instituto Portugues de Oncologia de Coimbra Francisco Gentil EPE

location_facility: Budgetary Healthcare Institution of Omsk Region - Clinical Oncological Dispensary

location_facility: Instituto de Investigaciones Clinicas Mar del Plata

location_facility: Centro de Investigaciones Clinicas. Clinica Viedma S.A.

location_facility: Wojewadzki Szpital Specjalistyczny w Biaej Podlaskiej SMO KO-MED CENTRA KLINICZNE SP. Z O.O.

location_facility: Reading Hospital McGlinn Cancer Institute

location_facility: Instituto Medico Especializado Alexander Fleming

location_facility: ASST Istituti Ospitalieri, Oncology Department

location_facility: Centrum Onkologii - Instytut im. Marii Sklodowskiej-Curie w Warszawie

type: Registry Identifier

title: A Phase 3, Open-label, Randomized, Noninferiority Trial of Subcutaneous Formulation of Nivolumab Versus Intravenous Nivolumab in Participants With Advanced or Metastatic Clear Cell Renal Cell Carcinoma Who Have Received Prior Systemic Therapy

summary: The purpose of this study is to evaluate the drug levels, efficacy, safety, and tolerability of subcutaneous nivolumab versus intravenous nivolumab in participants with previously treated clear cell renal cell carcinoma that is advanced or has spread.


ipd_sharing_description:
Qualified researchers may request access to individual patient level data through the request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/).

For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).

lead_sponsor: Hoffmann-La Roche

location_country:
Australia
Russian Federation
Denmark
Taiwan
France
Japan
Poland
Argentina
Canada
Korea, Republic of
Hong Kong
Netherlands
Switzerland
Bulgaria
Singapore
Hungary
Portugal
Germany
United States
United Kingdom
Italy
Austria
Mexico
Israel
Spain
Turkey

acronym: AVONELLE-X

location_facility: Hospital General de Catalunya; Servicio de oftalmologia

location_facility: Gloucestershire Hospitals NHS Foundation Trust

location_facility: Mid Atlantic Retina - Wills Eye Hospital

location_facility: Hospital Universitario Rio Hortega; Servicio de Oftalmologia

location_facility: Hospital de Sao Joao; Servico de Oftalmologia

location_facility: Kansai Medical University Medical Center

location_facility: Northwestern Medical Group/Northwestern University

location_facility: University Hospital Southampton NHS Foundation Trust; Southampton Eye Unit

location_facility: Queen Mary Hospital; Department of Ophthalmology

location_facility: "Intersec Research and Technology Complex Eye Microsurgery n a Fyodorov Novosibirsk Branch

location_facility: Hospital Universitario de Bellvitge; Servicio de oftalmologia

location_facility: Northern California Retina Vitreous Associates

location_facility: National Defense Medical College Hospital

location_facility: Retina Consultants of Southern California

location_facility: Hacettepe University Medical Faculty; Department of Ophthalmology

location_facility: University of British Columbia - Vancouver Coastal Health Authority

location_facility: SP ZOZ Szpital Uniwersytecki w Krakowie Oddział Kliniczny Okulistyki i Onkologii Okulistycznej

location_facility: University of California, Davis, Eye Center

location_facility: Szegedi Tudományegyetem ÁOK; Department of Ophtalmology

location_facility: Universitätsklinikum Freiburg, Klinik für Augenheilkunde

location_facility: Gazi University Faculty of Medicine; Department Of Ophthalmology

location_facility: California Eye Specialists Medical group Inc.

location_facility: Centro Hospitalar E Universitário de Coimbra EPE - Serviço Oftalmologia; Serviço Oftalmologia

location_facility: Rigshospitalet Glostrup; Afdeling for Øjensygdomme, Center for Forskning

location_facility: Hyogo Prefectural Amagasaki General Medical Center (Hyogo AGMC)

location_facility: Universitätkslinikum Düsseldorf, Augenklinik; Klinik fürAugenheilkunde

location_facility: Fondazione Irccs Ca' Granda Ospedale Maggiore Policlinico-Clinica Regina Elena;U.O.C Oculistica

location_facility: Szpital Specjalistyczny nr 1; Oddzial Okulistyki

location_facility: Chang Gung Medical Foundation - Linkou; Ophthalmology

location_facility: ASST FATEBENEFRATELLI SACCO; Oculistica (Sacco)

location_facility: Hopital de la croix rousse; Ophtalmologie

location_facility: Debreceni Egyetem Klinikai Kozpont; Szemeszeti Klinika

location_facility: Augenabteilung am St. Franziskus-Hospital

location_facility: Ankara University Medical Faculty; Department of Ophthalmology

location_facility: National University Hospital; Ophthalmology Department

location_facility: Magyar Honvedseg Egeszsegugyi Kozpont; Szemészeti Osztály

location_facility: Seoul National University Bundang Hospital

location_facility: Japanese Red Cross Nagasaki Genbaku Hospital

location_facility: Tokyo Medical University Hachioji Medical Center

location_facility: Instituto Oftalmologico Gomez Ulla; Servicio de Oftalmologia

location_facility: Pentagram Eye Hospital (Medical Center "Pentagram")

location_facility: Specialized Hospital for Active Treatment of Eye Diseases Zora

location_facility: Intersec Research and Technology Complex "Eye Microsurgery" n.a. S.N. Fyodorov; Cheboksary Branch

location_facility: Taipei Veterans General Hospital; Ophthalmology

location_facility: Bristol Eye Hospital;Retinal Treatment and Research Unit

location_facility: Sjællands Universitetshospital, Roskilde; Øjenafdelingen

location_facility: The Ohio State University Havener Eye Institute

location_facility: Clinica Universitaria de Navarra; Servicio de Oftalmologia

location_facility: UNIVERSITA' DEGLI STUDI DI GENOVA - Di.N.O.G.;CLINICA OCULISTICA

location_facility: Hospital Clinic de Barcelona; Consultas Externas Oftalmologia

location_facility: Hospital dos de maig; servicio de oftalmologia

location_facility: Moorfields Eye Hospital NHS Foundation Trust

location_facility: Gabinet Okulistyczny Prof Edward Wylegala

location_facility: Changhua Christian Hospital; Department of Ophthalmology

location_facility: Medizinische Universität Wien; Universitätsklinik für Augenheilkunde und Optometrie

location_facility: Ege University Medical Faculty; Department of Ophthalmology

location_facility: Shiga University Of Medical Science Hospital

location_facility: Hospital Universitario Miguel Servet; Servicio de Oftalmologia

location_facility: FSBI "Scientific Research Institute of Eye Diseases" of Russian Academy of medical Sciences

location_facility: Royal Liverpool University Hospital; St Paul's Clinical Eye Research Centre

location_facility: Centre Paradis Monticelli; Ophtalmologie

location_facility: University Retina and Macula Associates, PC

location_facility: Tokyo Women's Medical University Hospital

location_facility: Fondazione G.B. Bietti Per Lo Studio E La Ricerca in Oftalmologia-Presidio Ospedaliero Britannico

location_facility: Southeastern Retina Associates Chattanooga

title: A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Patients With Neovascular Age-Related Macular Degeneration (AVONELLE-X)

summary: This is a multicenter long-term extension study designed to evaluate the long-term safety and tolerability of faricimab 6 milligrams (mg) administered by intravitreal injection at a personalized treatment interval to participants with neovascular age-related macular degeneration who enrolled in and completed one of the Phase III studies: GR40306 (NCT03823287) or GR40844 (NCT03823300), also referred to as the parent studies. Eligible patients who consent to participate in this study will be enrolled upon completion of the end-of-study visit in the parent study.


title: A Phase 1/2, Open-label, Multicenter Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of CC-90011 in Combination With Venetoclax and Azacitidine in R/R Acute Myeloid Leukemia (AML) and Treatment-naïve Subjects With AML Who Are Not Eligible for Intensive Induction Chemotherapy

summary: CC-90011-AML-002 is a Phase 1/2, open-label, multicenter study to assess the safety, tolerability, and preliminary efficacy of CC-90011 given concurrently with Venetoclax and Azacitidine. This study will include 3 parts: a dose escalation part in R/R AML, a dose escalation part in ndAML (treatment-naïve participants with AML who are ≥ 75 years of age or are ≥ 18 to 74 years of age and otherwise not eligible for intensive induction chemotherapy), and a randomized dose expansion part in ndAML of Venetoclax and Azacitidine with or without CC-90011.

location_country:
Italy
Austria
France
Norway
Belgium
Spain
United States

location_facility: Salzburger Landkliniken St. Johanns-Spital

location_facility: Hospital Universitario Virgen del Rocio - PPDS

location_facility: University of Miami Miller School of Medicine Jackson Memorial Hospital

location_facility: Ohio State University Medical CenterJames Cancer Hospital

location_facility: Azienda Ospedaliero Universitaria Di Bologna - Policlinico S Orsola Malpighi

location_facility: Winship Cancer Institute of Emory University

location_facility: The University of Texas - MD Anderson Cancer Center

location_facility: Hospital General Universitario Gregorio Marañon

location_facility: Ospedale Santa Maria Della Misericordia Di Perugia

location_facility: Centre Hospitalier Lyon Sud - Hospices Civils de Lyon Groupement Hospitalier Sud


title: Randomised, Double-blind, Double-dummy, Multicentre Trial to Evaluate the Efficacy and Safety of Three Different Weekly Dosages of Calcifediol Versus Placebo in Subjects With Either Vitamin D Deficiency or Insufficiency.

acronym: WORFEROL

summary: This is a randomised, double-blind, double-dummy, multicentre, dose-ranging clinical trial in subjects with vitamin D deficiency or insufficiency. Its general objective is to determine the efficacy and safety of different doses of calcifediol soft gelatin capsules (SGCs) compared to placebo.

lead_sponsor: Faes Farma, S.A.

location_country: Italy Serbia France Czechia Bulgaria Slovakia Romania Spain

location_facility: Individual Practice Ambulatory for Specialized Medical Care - Cardiology, Obstetrics and Gynecology

location_facility: Hospital Universitario Quirónsalud Madrid

location_facility: Centrum gynekologické rehabilitace s.r.o.

location_facility: Kardioamb, s.r.o., Kardiologická a interná ambulancia

location_facility: MEDILEX, s.r.o., Ambulancia vnútorného lekárstva

location_facility: Zoll-Med, s.r.o., Ambulancia klinickej imunológie a alergológie

location_facility: Complejo Complejo Asistencial de Salamanca

location_facility: Fondazione IRCCS Cà Granda - Ospedale Maggiore Policlinico

location_facility: IN MEDIC s.r.o., Neurologická ambulancia

location_facility: AOU Policlinico Umberto I -Università Sapienza di Roma

location_facility: Cabinet Individual ''Dr. Roceanu Adina Maria''-Neurologie, Neurofiziologie

location_facility: Opšta bolnica "Đorđe Joanović" Zrenjanin, Odeljenje za reumatologiju

location_facility: Centrum pro diagnostiku a léčbu myasthenia gravis - Neurologická klinika 1. LF UK a VFN v Praze

location_facility: Klinički centar Kragujevac, Centar za reumatologiju, alergologiju i kliničku imunologiju, Odeljenje za reumatologiju

location_facility: Institut za lečenje i rehabilitaciju "Niška Banja" Niš, Klinika za reumatologiju

location_facility: Azienda Ospedaliero Universitaria Paolo Giaccone Palermo

location_facility: Klinički centar Vojvodine, Klinika za endokrinologiju, dijabetes i bolesti metabolizma

location_facility: Azienda Ospedaliero Universitaria - Università degli Studi della Campania Luigi Vanvitelli

location_facility: ANA JJ, s.r.o., Ambulancia klinickej imunológie a alergológie

location_facility: Poliklinika Choceň - Neurologická ambulance

location_facility: KK Neuro, s.r.o., Neurologická ambulancia

location_facility: Hospital Universitario Marqués de Valdecilla

location_facility: ALERSA, s.r.o., Ambulancia klinickej imunológie a alergológie

location_facility: RS centrum - Neurologická klinika 1.LF UK a VFN v Praze

location_facility: Hospital Torrecárdenas-Centro Periferico Bola Azul

location_facility: Medical Centre Asklepion - Research in human medicine

location_facility: KARDIO 1, s.r.o., Kardiologická ambulancia

location_facility: ALERGO H2B, s.r.o., Ambulancia klinickej imunológie a alergológie

location_facility: Specijalna bolnica za reumatske bolesti Novi Sad

location_facility: Oddělení ortopedie Nemocnice Pardubického kraje, a.s. Pardubická nemocnice

location_facility: S.C. Centrul Medical de Diagnostic si Tratament Ambulator NEOMED S.R.L

location_facility: Spitalul Clinic Judetean de Urgenta Craiova-Clinica de Medicina Fizica si Recuperare Medicala


title: A Multi-arm Phase 1b Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma

summary: The purpose of this study is to characterize the safety and tolerability of teclistamab when administered in different combination regimen and to identify the optimal dose(s) of teclistamab combination regimens.

ipd_sharing_description: The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

location_country:
France
Belgium
Australia
United States
United Kingdom

location_facility: Institut Universitaire du cancer de Toulouse-Oncopole

location_facility: Washington University School of Medicine

location_facility: Indiana University Melvin and Bren Simon Cancer Center


title: A Phase 2, Single-arm, Open-label Clinical Trial of Pembrolizumab Plus Lenvatinib in Participants With First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (nccRCC) (KEYNOTE-B61)

summary: This study is being performed as a single-arm open-label study in order to rapidly provide information on the potential benefits of the combination of pembrolizumab and lenvatinib in participants with previously untreated advanced/metastatic non-clear cell renal cell carcinoma.

lead_sponsor: Merck Sharp & Dohme Corp.

location_country:
Italy
United States
France
Poland
Hungary
Australia
Ireland
Russian Federation
Spain
Turkey
Canada
United Kingdom
Korea, Republic of
Ukraine

location_facility: Vanderbilt University Medical Center ( Site 0008)

location_facility: SHBI Leningrad Regional Clinical Oncology Dispensary-Clinical Trials Department ( Site 0607)

location_facility: Fundación Instituto Valenciano de Oncología-Oncologico ( Site 0202)

location_facility: Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 0201)

location_facility: Borsod-Abaúj-Zemplén Megyei Központi Kórház és Egyetemi Okta-Klinikai Onkológiai és Sugárterápiás C

location_facility: Jász-Nagykun-Szolnok Megyei Hetényi Géza Kórház-Onkologiai Kozpont ( Site 0303)

location_facility: Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 0903)

location_facility: CHU de Quebec - Université Laval - Hotel Dieu de Quebec ( Site 1502)

location_facility: Azienda Ospedaliera Universitaria Integrata Verona - Ospedale Borgo Roma-Oncology Unit ( Site 0902)

location_facility: Hacettepe Universitesi-oncology hospital ( Site 1101)

location_facility: Luxmed Onkologia sp. z o. o. ( Site 0802)

location_facility: Royal Brisbane and Women's Hospital-Medical Oncology Clinical Trials Unit, Cancer Care Services ( Si

location_facility: Tallaght University Hospital ( Site 1600)

location_facility: Memorial Sloan Kettering Cancer Center ( Site 0015)

location_facility: Institut de cancérologie Strasbourg Europe (ICANS) ( Site 1007)

location_facility: BC Cancer Vancouver-Clinical Trials Unit ( Site 1500)

location_facility: Fondazione Policlinico Universitario Agostino Gemelli-Medical Oncology ( Site 0901)

location_facility: Severance Hospital, Yonsei University Health System-Medical oncology ( Site 1302)

location_facility: Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie (

location_facility: St. Vincent Frontier Cancer Center ( Site 0004)

location_facility: Centre de Cancérologie du Grand Montpellier ( Site 1005)

location_facility: Nizhegorodsky Regional Oncology Dispensary, Branch #2-chemotherapy ( Site 0605)

location_facility: centre hospitalier lyon sud ( Site 1003)

location_facility: Ankara University Hospital Cebeci ( Site 1105)

location_facility: Russian Scientific Center of Radiology-Russian Scientific Center of Radiology ( Site 0602)

location_facility: Dnepropetrovsk Regional Clinical Hospital Mechnikov-Department of urology ( Site 0508)

location_facility: Országos Onkológiai Intézet-Urogenital Tumors Department and Clinical Pharmacology ( Site 0304)

location_facility: Szpital Kliniczny im. Przemienienia Panskiego Uniwersytetu M-chemotherapy department ( Site 0800)

location_facility: CNPE "Regional Center of Oncology"-oncourology department ( Site 0502)

location_facility: Göztepe Prof. Dr. Süleyman Yalçın Şehir Hastanesi-oncology ( Site 1103)

location_facility: Cherkasy Regional Oncology Dispensary ( Site 0504)

location_facility: Macquarie University-MQ Health Clinical Trials Unit ( Site 0405)

location_facility: Cambridge University Hospital ( Site 1200)

location_facility: Ege University Medicine of Faculty ( Site 1102)

location_facility: Ashford Cancer Centre Research ( Site 0404)

location_facility: Seattle Cancer Care Alliance ( Site 0014)

location_facility: Comprehensive Cancer Centers of Nevada ( Site 0010)

location_facility: Princess Margaret Cancer Centre ( Site 1504)

location_facility: MEDICAL COLLEGE OF WISCONSIN ( Site 0006)

location_facility: Istanbul Universitesi Cerrahpasa ( Site 1104)

location_facility: Sunnybrook Health Sciences Centre ( Site 1501)

location_facility: Hospital Universitario Ramón y Cajal-Medical Oncology ( Site 0200)

location_facility: Azienda Ospedaliera Santa Maria Terni-SC Oncologia ( Site 0900)

location_facility: Debreceni Egyetem Klinikai Kozpont-Onkológiai Klinika ( Site 0300)

location_facility: Georgetown University Medical Center ( Site 0001)

location_facility: Chernihiv Medical Center of Modern Oncology ( Site 0509)

location_facility: Volga District Medical Center-Urology Department ( Site 0604)

location_facility: Asan Medical Center-Department of Oncology ( Site 1300)


title: An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of TL-895 Combined With KRT-232 in Patients With Relapsed/Refractory (R/R) FLT3+ Acute Myeloid Leukemia (AML)

summary: This study evaluates TL-895, a potent, orally available and highly selective irreversible tyrosine kinase inhibitor combined with KRT-232, a novel oral small molecule inhibitor of MDM2 for the treatment of adults with FLT3 mutated Acute Myeloid Leukemia. Participants must be relapsed/refractory (e.g., having failed prior therapy) to be eligible for this study.

lead_sponsor: Telios Pharma, Inc.

location_country:
Italy
United States
France
Australia
Spain
Germany
Korea, Republic of

location_facility: Polyclinic S. Orsola-Malpighi, Operative Unit of Hematology

location_facility: University Clinical Hospital of Valencia, Department of Hematology and Medical Oncology

location_facility: Rush University Medical Center, Division of Hematology Oncology and Cell Therapy

location_facility: Romagnolo Scientific Institute of Meldola (IRST) S.r.l., Department of Oncology and Clinical and Experimental Haematology

location_facility: Hospital Universitario y Politécnico de La Fe

location_facility: University Hospital Halle (Saale), Department of Internal Medicine IV - Hematology and Oncology

location_facility: Thomas Jefferson University, Sidney Kimmel Cancer Center, Clinical Research Organization

location_facility: University of Sunshine Coast-Sippy Downs

location_facility: University of California, Irvine Medical Center

location_facility: University Duisburg-Essen, University Hospital Essen, Department of Internal Medicine


title: A Phase 1b, Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-64264681 in Combination With JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

summary: The primary purpose of this study is to determine: the recommended Phase 2 doses (RP2Ds) of JNJ-64264681 and JNJ 67856633 when administered together in participants with B cell non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) (Part A - Dose Escalation); and the safety of the RP2Ds for this combination in different histologies/participant populations (Part B - Cohort Expansion).

location_country:
Netherlands
France
Poland
Israel
Georgia
Belgium
Australia
Spain
Moldova, Republic of
United States
Korea, Republic of
Ukraine

location_facility:
Monash Medical Centre
Peter MacCallum Cancer Centre
Weill Cornell Medicine
CHRU de Lille - Hôpital Claude Huriez
Institut Curie
Memorial Sloan Kettering Cancer Center
Centre hospitalier Lyon-Sud
Uniwersyteckie Centrum Kliniczne
Scientia Clinical Research
Hosp. Univ. Fund. Jimenez Diaz
Hosp. Univ. Vall D Hebron
Pratia Onkologia Katowice
Samsung Medical Center
Sheba Medical Center
CHU UCL Namur - Site Godinne
Academic Medical Center
CHU Bretonneau
Stony Brook University Medical Center
Arensia Exploratory Medicine
Linear Clinical Research Ltd
Icahn School of Medicine at Mount Sinai
Chu Hotel Dieu
Pratia MCM Krakow
AZ St.-Jan Brugge-Oostende AV
Hadassah Medical Center
Universitair Ziekenhuis Gent - UZ GENT
Tel Aviv Sourasky MC
Seoul National University Hospital
Asan Medical Center
ARENSIA Exploratory Medicine Unit
Centrum Medyczne Pratia Poznan


title: A Randomized, Open Label Phase 2/3 Study Comparing Cobolimab + Dostarlimab + Docetaxel To Dostarlimab + Docetaxel To Docetaxel Alone In Participants With Advanced Nonsmall Cell Lung Cancer Who Have Progressed On Prior Anti-PD-(L)1 Therapy And Chemotherapy (COSTAR Lung)

acronym: COSTAR Lung

summary: This is a multi-center, parallel group treatment, Phase 2 open label study evaluating cobolimab in combination with dostarlimab and docetaxel in participants with advanced Nonsmall cell Lung Cancer (NSCLC) who have progressed on prior anti-PD-(L)1 therapy and chemotherapy.

ipd_sharing_description: IPD for this study will be made available via the Clinical Study Data Request site.

lead_sponsor: GlaxoSmithKline

location_country:
Italy
United States
Mexico
Germany
France
Poland
Argentina
Australia
Russian Federation
Spain
Canada
United Kingdom
Korea, Republic of


title: An Open-Label Extension Study to Evaluate Rozanolixizumab in Study Participants With Generalized Myasthenia Gravis

summary: The purpose of this study is to assess the safety, tolerability and efficacy of additional 6-week treatment cycles with rozanolixizumab in study participants with generalized myasthenia gravis (gMG).

status: Enrolling by invitation

ipd_sharing_description: Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.

lead_sponsor: UCB Biopharma SRL

location_country:
Italy
Serbia
Germany
France
Czechia
Japan
Poland
Georgia
Hungary
Russian Federation
Spain
Denmark
United States
Canada
Taiwan


ipd_sharing_description: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/

lead_sponsor: Bioverativ, a Sanofi company

location_country:
Italy
Netherlands
Spain
Germany
France
Bulgaria
Greece
Japan
Hungary
Belgium
Argentina
Australia
China
United States
United Kingdom
Canada

acronym: XTEND-ed

location_facility:
Investigational Site Number :2500005
Investigational Site Number :3480004
Investigational Site Number :5280001
Investigational Site Number :1560006
Investigational Site Number :2500001
Investigational Site Number :0320002
Investigational Site Number :7240001
Investigational Site Number :0360004
Investigational Site Number :8400003
Investigational Site Number :0320001
Investigational Site Number :3920422
Investigational Site Number :2500004
Investigational Site Number :0560003
Investigational Site Number :1560009
Investigational Site Number :1560005
Investigational Site Number :1560001
Investigational Site Number :1560010
Investigational Site Number :1560003
Investigational Site Number :1560007
Investigational Site Number :1560004
Investigational Site Number :3920423
Investigational Site Number :3920421
Investigational Site Number :3000001
Investigational Site Number :2500003
Investigational Site Number :2760302
Investigational Site Number :2760304
Investigational Site Number :2760001
Investigational Site Number :1560002
Investigational Site Number :1240005
Investigational Site Number :3920425
Investigational Site Number :0360003
Investigational Site Number :1000172
Investigational Site Number :1240004
Investigational Site Number :8260005
Investigational Site Number :2500006
Investigational Site Number :8400001
Investigational Site Number :1560013
Investigational Site Number :8400006
Investigational Site Number :3800001
Investigational Site Number :3920426

title: A Phase 3 Open-label, Multicenter Study of the Long-term Safety and Efficacy of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein (rFVIIIFc-VWF-XTEN; BIVV001) in Previously Treated Patients With Severe Hemophilia A

summary:
Primary Objective:

- To evaluate the long-term safety of BIVV001 in previously treated subjects with hemophilia A

Secondary Objectives:

To evaluate the efficacy of BIVV001 as a prophylaxis treatment.
To evaluate the efficacy of BIVV001 in the treatment of bleeding episodes.
To evaluate BIVV001 consumption for prevention and treatment of bleeding episodes.
To evaluate the effect of BIVV001 prophylaxis on joint health outcomes.
To evaluate the effect of BIVV001 prophylaxis on Quality of Life (QoL) outcomes.
To evaluate the safety and tolerability of BIVV001 treatment.
To assess the PK of BIVV001 based on the one stage activated partial thromboplastin time (aPTT) and two-stage chromogenic FVIII activity assays (only applicable to Arm B).
To evaluate the efficacy of BIVV001 for perioperative management


title: A Phase III Randomized, Open-Label Active Comparator-Controlled Multicenter Study to Evaluate Efficacy and Safety of Obinutuzumab in Patients With Primary Membranous Nephropathy

summary: This study will evaluate the efficacy, safety, pharmacodynamics, and pharmacokinetics (PK) of obinutuzumab compared with tacrolimus in participants with primary membranous nephropathy (pMN).

ReferenceType: derived

ReferenceCitation: Dossier C, Hogan J. Response to Majeranowski. Pediatr Nephrol. 2021 Jun;36(6):1653. doi: 10.1007/s00467-021-04982-4. Epub 2021 Mar 10.

family: Dossier

full_name: Claire Dossier

given: Claire

sequence: first

family: Hogan

full_name: Julien Hogan

given: Julien

sequence: additional

bso_classification: Social sciences

datasource: user

genre: journal-article

genre_raw: journal-article

journal_name: Pediatric Nephrology

oa_host_type: publisher

evidence: open (via free pdf)

host_type: publisher

license_normalized: no license

version: publishedVersion

publisher: Springer Science and Business Media LLC

publisher_dissemination: Springer-Nature

publisher_group: Springer-Nature

publisher_normalized: Springer

title: Response to Majeranowski

ipd_sharing_description: Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).

location_country:
Italy
Brazil
Peru
Spain
France
Poland
Israel
Argentina
Russian Federation
China
Turkey
United States
Ukraine

location_facility: Policlinico di Bari; Divisione di Nefrologia, Dialisi e Trapianto

location_facility: Hospital General Universitaro Gregorio Marañon ;Servicio de Nefrologia

location_facility: Kaiser Permanente - San Francisco Medical Center

location_facility: Hospital Universitari Vall d'Hebron; Servicio de Nefrologia

location_facility: Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wroclawiu; Klinika Nefrologii

location_facility: Tongji Hospital Tongji Medical College Huazhong University of Science and Technology

location_facility: Hospital do Rim e Hipertensão - Fundação Oswaldo Ramos

location_facility: Mayo Clinic; Nephrology and Hypertension

location_facility: Louisiana State University Health Sciences Center in New Orleans; Section of Nephrology

location_facility: Henry Ford Hospital; Div of Nephrology & Hypertension

location_facility: ASST Monza - Ospedale San Gerardo; Clinica Nefrologica

location_facility: Institute of Nephrology NAMS of Ukraine; Department of Nephrology, Dialysis and IT Support

location_facility: Hadassah Medical Orgainastion; Nephrology

location_facility: Szpital Uniwersytecki im.dr.A.Jurasza w Bydgoszczy; Klinika Nefrologii, Nadcisnienia Tetniczego

location_facility: The First Affiliated Hospital of Xian Jiao Tong University

location_facility: Hospital Clinic i Provincial; Servicio de Nefrologia

location_facility: Hospital Italiano de Buenos Aires; Rheumatology department

location_facility: Uniwersytecki Szpital Kliniczny w Bialymstoku; II Klinika Nefrologii

location_facility: Keck School of Medicine - University of Southern California

location_facility: Chinese People's Liberation Army Eastern Theater General Hospital

location_facility: Hacettepe Uni School of Medicine; Nephrology

location_facility: Hospital Universitario 12 de Octubre; Servicio de Nefrologia

location_facility: A.O. Spedali Civili Di Brescia-P.O. Spedali Civili; Nefrologia

location_facility: Uniwersytecki Szpital Kliniczny nr 1 im. N. Barlickiego; Oddzial Nefrologii

location_facility: Hospital das Clinicas - FMUSP; Nefrologia

location_facility: Autonomous non-commercial organization "Medical Research Center of Drug Therapy "Yuninova"

location_facility: Accel Research Sites; Mid-Florida Kidney and Hypertension Care

location_facility: Hospital Britanico Buenos Aires; Rheumatology Service

location_facility: Ser Servicos Especializados Em Reumatologia

location_facility: Regional Clinical Hospital n.a I.I. Mechnicov

location_facility: SPSK Slaskiego UM w Katowicach; Katedra i Klinika Nefrologii, Endokryn.I Chorob Przemiany Materii

location_facility: Nanfang Hospital, Southern Medical University

location_facility: West China Hospital - Sichuan University

location_facility: Hospital de Base de Sao Jose do Rio Preto

location_facility: Ospedale San Giovanni Bosco; Unita Operativa Nefrologia Dialisi

location_facility: A.O. U. Federico II; U.O. di Nefrologia - Dipartimento di Sanità Pubblica

location_facility: The 1st Affiliated hospital of Fujian Medical University

location_facility: Rambam Medical Center; Department of Nephrology and Hypertension

location_facility: Uniwersytecki Szpital Kliniczny im WAM CSW; Klinika Nefrologii i Transplantologii Nerek

location_facility: Istanbul Florence Nightingale Hospital; Nephrology

location_facility: Hopital Bichat Claude Bernard; Nephrologie

location_facility: Istanbul University Istanbul Medical Faculty; Department of Internal Medicine

location_facility: Penn State Univ. Milton S. Hershey Medical Center

location_facility: Hospital Universitari de Bellvitge; Servicio de Nefrologia

location_facility: General Hospital of Ningxia Medical University

location_facility: First Moscow State Medical University n.a. I.M. Sechenov

location_facility: Hospital Universitario Dr. Peset; Servicio de Nefrologia

location_facility: HOPITAL HENRI MONDOR; SERVICE DE Nephrologie

location_facility: Hopital Rangueil; Service de Nephrologie & D'Immunologie Clinique

location_facility: Ruijin Hospital, Shanghai Jiaotong University School of Medicine

location_facility: Akdeniz University Medical Faculty; Internal Medicine, Nephrology


type: Other Grant/Funding Number

type: U.S. NIH Grant/Contract

title: A Phase II/III Randomized, Double-Blind, Placebo-Controlled, Cognitive Endpoint, Multi-Center Study of Potential Disease Modifying Therapies in Individuals at Risk for and With Dominantly Inherited Alzheimer's Disease

acronym: DIAN-TU

summary:
The purpose of this study is to assess the safety, tolerability, biomarker and cognitive efficacy of investigational products in subjects who are known to have an Alzheimer's disease-causing mutation by determining if treatment with the study drug slows the rate of progression of cognitive impairment and improves disease-related biomarkers.

This is an analysis study for an MPRP: DIAN-TU-001 Master NCT01760005

status: Completed

study_completion_date_type: Actual

ReferenceType: background

ReferenceCitation: Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM, Holtzman DM, Santacruz A, Buckles V, Oliver A, Moulder K, Aisen PS, Ghetti B, Klunk WE, McDade E, Martins RN, Masters CL, Mayeux R, Ringman JM, Rossor MN, Schofield PR, Sperling RA, Salloway S, Morris JC; Dominantly Inherited Alzheimer Network. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med. 2012 Aug 30;367(9):795-804. doi: 10.1056/NEJMoa1202753. Epub 2012 Jul 11. Erratum in: N Engl J Med. 2012 Aug 23;367(8):780.

ReferenceCitation: Farlow M, Arnold SE, van Dyck CH, Aisen PS, Snider BJ, Porsteinsson AP, Friedrich S, Dean RA, Gonzales C, Sethuraman G, DeMattos RB, Mohs R, Paul SM, Siemers ER. Safety and biomarker effects of solanezumab in patients with Alzheimer's disease. Alzheimers Dement. 2012 Jul;8(4):261-71. doi: 10.1016/j.jalz.2011.09.224. Epub 2012 Jun 5.

ReferenceCitation: Bateman RJ, Benzinger TL, Berry S, Clifford DB, Duggan C, Fagan AM, Fanning K, Farlow MR, Hassenstab J, McDade EM, Mills S, Paumier K, Quintana M, Salloway SP, Santacruz A, Schneider LS, Wang G, Xiong C; DIAN-TU Pharma Consortium for the Dominantly Inherited Alzheimer Network. The DIAN-TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model. Alzheimers Dement. 2017 Jan;13(1):8-19. doi: 10.1016/j.jalz.2016.07.005. Epub 2016 Aug 29.

ReferenceCitation: Mills SM, Mallmann J, Santacruz AM, Fuqua A, Carril M, Aisen PS, Althage MC, Belyew S, Benzinger TL, Brooks WS, Buckles VD, Cairns NJ, Clifford D, Danek A, Fagan AM, Farlow M, Fox N, Ghetti B, Goate AM, Heinrichs D, Hornbeck R, Jack C, Jucker M, Klunk WE, Marcus DS, Martins RN, Masters CM, Mayeux R, McDade E, Morris JC, Oliver A, Ringman JM, Rossor MN, Salloway S, Schofield PR, Snider J, Snyder P, Sperling RA, Stewart C, Thomas RG, Xiong C, Bateman RJ. Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial. Rev Neurol (Paris). 2013 Oct;169(10):737-43. doi: 10.1016/j.neurol.2013.07.017. Epub 2013 Sep 6. Review.

ReferenceCitation: Wang G, Berry S, Xiong C, Hassenstab J, Quintana M, McDade EM, Delmar P, Vestrucci M, Sethuraman G, Bateman RJ; Dominantly Inherited Alzheimer Network Trials Unit. A novel cognitive disease progression model for clinical trials in autosomal-dominant Alzheimer's disease. Stat Med. 2018 Sep 20;37(21):3047-3055. doi: 10.1002/sim.7811. Epub 2018 May 14.

ReferenceCitation: Weninger S, Carrillo MC, Dunn B, Aisen PS, Bateman RJ, Kotz JD, Langbaum JB, Mills SL, Reiman EM, Sperling R, Santacruz AM, Tariot PN, Welsh-Bohmer KA. Collaboration for Alzheimer's Prevention: Principles to guide data and sample sharing in preclinical Alzheimer's disease trials. Alzheimers Dement. 2016 May;12(5):631-2. doi: 10.1016/j.jalz.2016.04.001.

ReferenceCitation: Grill JD, Bateman RJ, Buckles V, Oliver A, Morris JC, Masters CL, Klunk WE, Ringman JM; Dominantly Inherited Alzheimer's Network. A survey of attitudes toward clinical trials and genetic disclosure in autosomal dominant Alzheimer's disease. Alzheimers Res Ther. 2015 Jul 22;7(1):50. doi: 10.1186/s13195-015-0135-0. eCollection 2015.

ReferenceCitation: McDade E, Bateman RJ. Stop Alzheimer's before it starts. Nature. 2017 Jul 12;547(7662):153-155. doi: 10.1038/547153a.

ReferenceCitation: McDade E, Wang G, Gordon BA, Hassenstab J, Benzinger TLS, Buckles V, Fagan AM, Holtzman DM, Cairns NJ, Goate AM, Marcus DS, Morris JC, Paumier K, Xiong C, Allegri R, Berman SB, Klunk W, Noble J, Ringman J, Ghetti B, Farlow M, Sperling RA, Chhatwal J, Salloway S, Graff-Radford NR, Schofield PR, Masters C, Rossor MN, Fox NC, Levin J, Jucker M, Bateman RJ; Dominantly Inherited Alzheimer Network. Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease. Neurology. 2018 Oct 2;91(14):e1295-e1306. doi: 10.1212/WNL.0000000000006277. Epub 2018 Sep 14.

ReferenceCitation: Ryman DC, Acosta-Baena N, Aisen PS, Bird T, Danek A, Fox NC, Goate A, Frommelt P, Ghetti B, Langbaum JB, Lopera F, Martins R, Masters CL, Mayeux RP, McDade E, Moreno S, Reiman EM, Ringman JM, Salloway S, Schofield PR, Sperling R, Tariot PN, Xiong C, Morris JC, Bateman RJ; Dominantly Inherited Alzheimer Network. Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. Neurology. 2014 Jul 15;83(3):253-60. doi: 10.1212/WNL.0000000000000596. Epub 2014 Jun 13. Review.

ReferenceCitation: Weng H, Bateman R, Morris JC, Xiong C. Validity and power of minimization algorithm in longitudinal analysis of clinical trials. Biostat Epidemiol. 2017;1(1):59-77. doi: 10.1080/24709360.2017.1331822. Epub 2017 Jun 13.

ipd_sharing_description: Access to DIAN-TU trial data will follow the DIAN-TU data access policy, which complies with the guidelines established by the Collaboration for Alzheimer's Prevention [CAP REF].

lead_sponsor: Washington University School of Medicine

location_country:
United States
France
Ireland
Australia
Puerto Rico
Spain
Canada
United Kingdom

location_facility: University of California San Diego Medical Center

location_facility: The National Hospital for Neurology and Neurosurgery

location_facility: University of Puerto Rico, School of Medicine

location_facility: Hospital Clínic I Provincial de Barcelona

location_facility: The McCuster Foundation of Alzheimer's Disease Research

lead_sponsor_type: academique

status_simplified: Completed


ipd_sharing_description: Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

lead_sponsor: Eli Lilly and Company

location_country:
Italy
India
Mexico
Germany
France
Japan
Puerto Rico
Spain
Denmark
United States

location_facility: Hospital Clínico Universitario de Valencia

location_facility: Hospital Infantil de Mexico Federico Gomez

location_facility: AMITA Health - Alexian Brothers Neurosciences Institute Clinical Research

location_facility: Rehabilitation & Neurological Services LLC

location_facility: Children Mercy Pediatric Clinical Research Unit

location_facility: Centro de Investigacion Medica Aguascalientes

location_facility: P. D. Hinduja National Hospital & Medical Research Centre

location_facility: Orange County Research Institute - Ontario

location_facility: Houston Neurology Clinical & Diagnostic Consultants

location_facility: Barrow Neurological Institute at Phoenix Children's Hospital

location_facility: CHRU de Lille - Service de neuropédiatrie

location_facility: Hospital Civil De Guadalajara Fray Antonio Alcalde

location_facility: Northwell Health- Division of Pediatric Neurology

location_facility: University of Texas Southwestern Medical Center at Dallas

location_facility: University of Kentucky College of Medicine

location_facility: Mangala Hospital & Mangala Kidney Foundation

location_facility: Hospital Clinico Universitario de Valladolid

location_facility: G.B. Pant Institute of Postgraduate Medical Education & Research

location_facility: Kokilaben Dhirubhai Ambani Hospital & Medical Research Institute

location_facility: Università degli Studi di Roma La Sapienza - Policlinico Umberto I

location_facility: PanAmerican Clinical Research S.A.de C.V. Guadalajara

location_facility: All India Institute of Medical Sciences - Nagpur

title: A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adolescent Patients 12 to 17 Years of Age With Chronic Migraine - the REBUILD-2 Study

summary: The main purpose of this study is to evaluate the efficacy and safety of galcanezumab for the preventive treatment of chronic migraine in participants 12 to 17 years of age. The primary objective is to demonstrate the superiority of galcanezumab versus placebo in the reduction of monthly migraine headache days across the 3-month double-blind treatment period.


lead_sponsor: Arena Pharmaceuticals

location_country:
Italy
Spain
Germany
France
Bulgaria
Czechia
Israel
Georgia
Korea, Republic of
Hungary
Belgium
Australia
Poland
Belarus
Russian Federation
United States
Canada
Portugal
Ukraine

acronym: GLADIATOR UC

location_facility: Communal Non-commercial Enterprise City Clinical Hospital #13 of Kharkiv City Council, Department of Gastroenterology

location_facility: CNE Regional Clinical Hosptial of Ivano-Frankivsk Regional Council, Department of Gastroenterology

location_facility: Centro Hospitalar Universitario de Sao Joao, E.P.E.

location_facility: Endoexpert Egészségügyi Szolgáltató Kft.

location_facility: LTD Academician Nikoloz Kipshideze Central University Clinic

location_facility: Allmedica Badania Kliniczne Sp. z.o.o. Sp.k.

location_facility: EuroMediCare Szpital Specjalistyczny z Przychodnia we Wroclawiu

location_facility: Autonomous Noncommercial Medical Organization "Stavropol Regional Clinical Advisory-Diagnostic Centre"

location_facility: University of Calgary, Heritage Medical Research Clinic

location_facility: CNE Kyiv City Clinical Hospital #1 of Executive Body of Kyiv City Council (Kyiv City State Administration), Dept of Therapy #2

location_facility: Debreceni Egyetem Klinikai Kozpont, Belgyogyaszati Klinika, Gasztroenterologia

location_facility: Private Institution, Educational Organization of Higher Education "Medical University Reaviz"

location_facility: Centre Hospitalier Universitaire de Clermont-Ferrand-Hopital Estaing

location_facility: Texas Digestive Disease Consultants, PLLC d/b/a GI Alliance

location_facility: Texas Digestive Disease Consultants d/b/a GI Alliance

location_facility: Centre Hospitalier Universitaire de Nice - Hopital de l'Archet2

location_facility: Centre Hospitalier Universitaire de Genoble Alpes - CHU Michallon

location_facility: Severance Hospital, Yonsei University Health System

location_facility: CNE Andrii Novak Transcarpathian Regional Clinical Hospital of Transcarpathian Reg Council, Department of Gastroenterology

location_facility: Scientific and Research Institute of Invalid Rehabilitation of National Pirogov

location_facility: Municipal Enterprise Dnipro Reg Council,Dept of Gastro (Hepatology)

location_facility: Medical Center of LLC Health Clinic, Med Clinical Investigational Center, Unit of Gastroenterology, Hepatology and Endocrinology

location_facility: ASST Rhodense U.O.C di Gastroenterologia ed Endoscopia Digestiva

location_facility: Acibadem City Clinic University Hospital EOOD

location_facility: CNE "Vinnytsia Reg Clinical Hosp Named After Pirogov Vinnystsia Regoinal Council", Reg Specialized Clinical Center of Gastro

location_facility: Centre Hospitalier Universitaire de Rennes - Hopital Pontchaillou

location_facility: JSC Infectious Diseases, AIDS and Clinical Immunology Research Center

location_facility: Washington University School of Medicine

location_facility: Hospital General Universitario de Alicante

location_facility: Ospedale San Bortolo-UOC di Gastroenterologia Vicenza

location_facility: Health Care Institution "Vitebsk Regional Clinical Specialized Center"

location_facility: Health Care Institution "Grodno City Clinical Hospital #4"

location_facility: LTD Israeli-Georgian Medical Research Clinic Helsicore

location_facility: Diagnostic-Consultative Center I - Sliven, EOOD

location_facility: Centre Hospitalier Universitaire de Nantes - Hotel-Dieu

location_facility: CNE Prof. O.O. Shalimov City Clinical Hospital #2 of Kharkiv City Council, Department of Proctology

location_facility: Kyungpook National University Chilgok Hospital

location_facility: Centralny Szpital Kliniczny MSWiA w Warszawie

location_facility: Twoja Przychodnia-Szczecinskie Centrum Medyczne

location_facility: FSBEI of Higher Education "North-Western State Medical University n.a. I.I. Mechnikov" of MoH RF

location_facility: Institution "Gomel Regional Clinical Hospital"

location_facility: Yonsei University Wonju Severance Christian Hospital

location_facility: Gastrointestinal Biosciences Clinical Trials, LLC

location_facility: LLC Academic Pridon Todua Medical Center - LLC Research Institute of Clinical Medicine

location_facility: Gut P.C., dba Digestive Health Specialists

location_facility: Diagnostic Consultation Center CONVEX EOOD

location_facility: SBHI of Nizhniy Novgorod region "Nizhniy Novgorod Regional Clinical Hospital n.a. N.A. Semashko

location_facility: LTD Malkhaz Katsiashvili Multiprofile Emergency Medicine Center

location_facility: Semmelweis Egyetem Belgyogyaszati es Hematologiai Klinika

title: A Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects With Moderately Active Ulcerative Colitis

summary: The purpose of this study is to determine whether oral etrasimod is a safe and effective treatment for moderately active ulcerative colitis in adult participants.


title: A Phase 1 Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations

summary: This is an open-label, multi-center Phase 1 study of LY3410738, an oral, covalent IDH inhibitor, in patients with IDH1 and/or IDH2-mutant advanced hematologic malignancies who have received standard therapy

location_country:
United States
Germany
France
Israel
Singapore
Belgium
Australia
Spain
Canada
Korea, Republic of
Taiwan

location_facility: University of California, Davis - Health Systems

location_facility: Centre hospitalier universitaire de Haut Leveque

location_facility: University of Texas MD Anderson Cancer Center

location_facility: Hospital Universitario La Fe de Valencia


title: A Phase 2b, Open-label, Single-arm, Multi-centre Study Assessing the Efficacy and Safety of Adavosertib as Treatment for Recurrent or Persistent Uterine Serous Carcinoma

acronym: ADAGIO

summary: This Phase 2b study aims to evaluate the efficacy and safety of adavosertib, an inhibitor of the tyrosine kinase WEE1, in subjects with recurrent or persistent uterine serous carcinoma (USC) who have previously received at least 1 prior platinum-based chemotherapy regimen for the management of USC.

status: Active, not recruiting

ReferenceCitation: Liu J, Oza AM, Colombo N, Oaknin A. ADAGIO: a phase IIb international study of the Wee1 inhibitor adavosertib in women with recurrent or persistent uterine serous carcinoma. Int J Gynecol Cancer. 2021 Oct 29. pii: ijgc-2021-003144. doi: 10.1136/ijgc-2021-003144. [Epub ahead of print]

family: Liu

full_name: Joyce Liu

given: Joyce

family: Oza

full_name: Amit M Oza

given: Amit M

family: Colombo

full_name: Nicoletta Colombo

given: Nicoletta

family: Oaknin

full_name: Ana Oaknin

given: Ana

bso_classification: Medical research

journal_name: International Journal of Gynecologic Cancer

publisher: BMJ

publisher_dissemination: British Medical Journal

publisher_group: British Medical Journal

publisher_normalized: British Medical Journal

ipd_sharing_description:
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

lead_sponsor: AstraZeneca

location_country:
Italy
United States
France
Spain
Germany
Canada


location_country:
Austria
Brazil
Switzerland
Netherlands
Germany
Finland
France
Japan
Australia
Belgium
Russian Federation
Spain
United States

acronym: Phase 3 Study of MK-6482 in Combination With Lenvatinib Versus Cabozantinib for Treatment of RCC

location_facility: Northwell Health- Monter Cancer Center ( Site 0013)

location_facility: Complejo Hospitalario Universitario A Coruna ( Site 1502)

location_facility: Providence Saint John's Health Center ( Site 0083)

location_facility: Memorial Sloan Kettering Cancer Center ( Site 0055)

location_facility: Cedars Sinai Medical Center ( Site 0027)

location_facility: Institut de Cancerologie de l Ouest Site Paul Papin ( Site 1200)

location_facility: Peter MacCallum Cancer Centre ( Site 4010)

location_facility: Rush University Medical Center ( Site 0040)

location_facility: Norton Cancer Institute - St. Matthews ( Site 0065)

location_facility: Sapporo Medical University Hospital ( Site 5008)

location_facility: Cancer Partners of Nebraska ( Site 0086)

location_facility: Hamamatsu University School of Medicine University Hospital ( Site 5004)

location_facility: Hospital Clinico San Carlos ( Site 1504)

location_facility: Volgograd Regional Uronephrological Center ( Site 2615)

location_facility: Zuyderland Medical Centre-Trialbureau Interne Geneeskunde ( Site 1904)

location_facility: Hospital Santa Creu i Sant Pau ( Site 1501)

location_facility: Tampereen yliopistollinen sairaala ( Site 1801)

location_facility: Universitair Medisch Centrum Utrecht ( Site 1910)

location_facility: Amphia Hospital Location Molengracht ( Site 1912)

location_facility: HELIOS Klinikum Berlin-Buch ( Site 1311)

location_facility: Lahey Hospital & Medical Center ( Site 0090)

location_facility: Antoni van Leeuwenhoek Ziekenhuis ( Site 1901)

location_facility: Nippon Medical School Hospital ( Site 5006)

location_facility: Confluence Health | Wenatchee Valley Hospital & Clinics ( Site 0061)

location_facility: Istituto Oncologica della Svizzera Italiana (IOSI) ( Site 1604)

location_facility: Tokyo Medical And Dental University Medical Hospital ( Site 5009)

location_facility: Georgetown University Medical Center ( Site 0006)

location_facility: Blue Ridge Cancer Care - Roanoke ( Site 0043)

location_facility: Hospital Clinic i Provincial ( Site 1500)

location_facility: Krankenhaus Martha Maria Halle-Doelau ( Site 1314)

location_facility: Cancer & Hematology Centers of Western Michigan ( Site 0018)

location_facility: Universitaetsspital Zuerich ( Site 1601)

location_facility: University of Texas, Southwestern Medical Center ( Site 0015)

location_facility: Real e Benemerita Associacao Portuguesa de Beneficencia ( Site 0311)

location_facility: MEDSI Clinical Hospital on Pyatnitsky Highway-Departmentof Antitumor Drug therapy ( Site 2618)

location_facility: Hadassah Medical-Oncology department ( Site 2609)

location_facility: Centro Gaucho Integrado de Oncologia ( Site 0304)

location_facility: Yaroslavl Regional Cancer Hospital-Oncology ( Site 2619)

location_facility: Peninsula Health Frankston Hospital ( Site 4001)

location_facility: Ivanovo Regional Oncology Dispensary ( Site 2616)

location_facility: Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 1507)

location_facility: Hopitaux Universitaires de Geneve HUG ( Site 1602)

location_facility: Klinik Ottakring-1.Medizinische Abteilung - Zentrum für Onkologie und Hämatologie ( Site 1031)

location_facility: University Cancer & Blood Center, LLC ( Site 0057)

location_facility: Charite Universitaetsmedizin Berlin ( Site 1321)

location_facility: Medizinische Universitätsklinik Graz ( Site 1051)

location_facility: Hospital General Universitario Gregorio Maranon ( Site 1505)

location_facility: Yokohama City University Hospital ( Site 5007)

location_facility: Nara Medical University Hospital ( Site 5002)

location_facility: SHI of Moscow City Oncology Clinical Hospital - 62 ( Site 2614)

location_facility: National Cancer Center Hospital East ( Site 5000)

location_facility: Liga Norte Riograndense Contra o Cancer ( Site 0313)

location_facility: Rutgers Cancer Institute of New Jersey ( Site 0078)

location_facility: Ironwood Cancer & Research Centers ( Site 0077)

location_facility: University of Vermont Medical Center ( Site 0001)

location_facility: Krankenhaus der Barmherzigen Brüder Wien ( Site 1041)

location_facility: Universitaetsklinikum Aachen AOER ( Site 1317)

location_facility: Helios Klinikum Erfurt GmbH ( Site 1315)

location_facility: Lehigh Valley Hospital- Cedar Crest-Oncology Clinical Trials ( Site 0056)

location_facility: FSBI United Hospital with Polyclinic ( Site 2613)

location_facility: Medizinische Universitaet Wien ( Site 1021)

location_facility: Cancer Research Center - HealthPartners/Park Nicollet-Oncology Research - Park Nicollet ( Site 0005)

location_facility: AdventHealth Orlando-AdventHealth Medical Group Hematology & Oncology at Orlando ( Site 0003)

location_facility: UCLA Hematology/Oncology - Santa Monica ( Site 0048)

title: An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination With Lenvatinib (MK-7902) vs Cabozantinib in Participants With Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 Therapy

summary:
This study will compare the efficacy and safety of belzutifan + lenvatinib versus cabozantinib in participants with advanced renal cell carcinoma (RCC) with clear cell component after prior therapy.

The primary hypothesis is that belzutifan + lenvatinib is superior to cabozantinib in terms of progression-free survival or overall survival.


title: A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of the Safety, Tolerability, Pharmacokinetics, and Therapeutic Efficacy of SAR441344 in Adult Patients With Primary Sjögren's Syndrome (pSjS)

acronym: phaethuSA

summary:
Primary Objective:

To evaluate the therapeutic efficacy of one dose level of SAR441344 versus placebo over 12 weeks in adult patients with primary Sjögren's syndrome (pSjS), assessed by the change of the European League Against Rheumatism (EULAR) Sjögren's Syndrome Disease Activity Index (ESSDAI)

Secondary Objectives:

To evaluate the therapeutic efficacy of one dose level of SAR441344 versus placebo over 12 weeks in adult patients with pSjS
To evaluate the therapeutic efficacy on fatigue of one dose level of SAR441344 versus placebo over 12 weeks in adult patients with pSjS
To evaluate the pharmacokinetic (PK) exposure of one dose level of SAR441344 over 12 weeks in adult patients with pSjS
To evaluate the safety and tolerability of one dose level of SAR441344 versus placebo in adult patients with pSjS as determined by adverse events (AEs)
To evaluate the local tolerability of one dose level of SAR441344 versus placebo over 12 weeks in adult patients with pSjS
To evaluate the safety and tolerability of one dose level of SAR441344 versus placebo over 12 weeks in adult patients with pSjS determined by electrocardiogram, vital signs, and laboratory evaluations
To measure the immunogenicity of one dose level of SAR441344 versus placebo over 12 weeks in adult patients with pSjS

This is a multicenter, randomized, double blind, placebo controlled, parallel group proof of concept Phase 2 study to evaluate the therapeutic efficacy of SAR441344 in adult patients with primary Sjögren's syndrome (pSjS), as well as safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD).

Study visit frequency: every 2 weeks in the treatment period and every 4 weeks in the follow-up period.
The total duration of the study will be 24 weeks (28 weeks including maximum screening duration) for each participant, including a 12-week treatment period and a 12-week follow-up period.

lead_sponsor: Sanofi

location_country:
United States
Mexico
Germany
France
Hungary
Belgium
Argentina
Spain
Canada
Korea, Republic of
Taiwan

location_facility:
Investigational Site Number :4840001
Investigational Site Number :0560001
Investigational Site Number :2500005
Investigational Site Number :3480004
Investigational Site Number :3480001
Investigational Site Number :2500001
Investigational Site Number :4100002
Investigational Site Number :0320002
Investigational Site Number :7240001
Investigational Site Number :0320001
Investigational Site Number :4100004
Investigational Site Number :0320003
Investigational Site Number :2500004
Investigational Site Number :1240001
Investigational Site Number :7240002
Investigational Site Number :3480003
Investigational Site Number :4840003
Investigational Site Number :7240003
Investigational Site Number :1580001
Investigational Site Number :2500003
Investigational Site Number :2760001
Investigational Site Number :4840002
Investigational Site Number :1580005
Investigational Site Number :1580002
Investigational Site Number :2500002
Investigational Site Number :8400001
Investigational Site Number :1580003
Investigational Site Number :4100001
Investigational Site Number :0560002
Investigational Site Number :8400005


location_country:
Brazil
Chile
Hong Kong
Mexico
Spain
France
Czechia
Japan
Poland
Romania
Singapore
Argentina
Australia
New Zealand
Russian Federation
Turkey
Korea, Republic of
Taiwan
Colombia

location_facility: Masarykuv onkologicky ustav-Klinika komplexni onkologicke pece

location_facility: Fakultni nemocnice Hradec Kralove-Klinika onkologie a radioterapie

location_facility: Fakultni Thomayerova nemocnice - Onkologicka klinika 1. LF UK

title: A Phase 2, Randomized, Open-label Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Hepatocellular Carcinoma Who Are Naive to IO Therapy But Progressed on Tyrosine Kinase Inhibitors (RELATIVITY-073)

summary: The purpose of this study is to evaluate the effectiveness and safety of relatlimab in combination with nivolumab in participants with advanced liver cancer who have never been treated with immuno-oncology therapy, after prior treatment with tyrosine kinase inhibitor therapy.


title: A Modular Phase 2a Multicentre Open-Label Study to Investigate DNA-damage Response Agents (or Combinations) in Patients With Advanced Cancer Whose Tumours Contain Molecular Alterations (PLANETTE)

summary: The study is investigating efficacy, safety and tolerability of DNA-damage Response Agents (or Combinations), in participants with advanced/metastatic solid malignancies whose tumours contain molecular alterations

ipd_sharing_description:
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the requests portal. All request will be evaluated as per the AZ disclosure commitment:

https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

location_country:
United States
France
Spain


lead_sponsor: Alexion Pharmaceuticals

location_country:
Italy
France
Japan
Spain
United States
United Kingdom
Korea, Republic of

acronym: Ravulizumab in Pediatric Participants with TMA after HSCT

location_facility:
Clinical Trial Site
Clinical Study Site

title: A Phase 3, Open-label, Single Arm, Multicenter Study of Ravulizumab in Addition to Best Supportive Care in Pediatric Participants With Thrombotic Microangiopathy (TMA) After Hematopoietic Stem Cell Transplantation (HSCT)

summary: This study will evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of ravulizumab administered by intravenous infusion to pediatric participants, from 1 month to < 18 years of age, with HSCT-TMA. The treatment period is 26 weeks, followed by a 26-week off-treatment follow-up period.


title: A Phase III, Double-blind, Randomised Study to Assess Switching to AZD9833 (a Next Generation, Oral SERD) + CDK4/6 Inhibitor (Palbociclib or Abemaciclib) vs Continuing Aromatase Inhibitor (Letrozole or Anastrozole)+ CDK4/6 Inhibitor in HR+/HER2-MBC Patients With Detectable ESR1Mutation Without Disease Progression During 1L Treatment With Aromatase Inhibitor+ CDK4/6 Inhibitor- A ctDNA Guided Early Switch Study

summary: The study is intended to show superiority of AZD9833 in combination with CDK4/6 inhibitor (palbociclib or abemaciclib) versus aromatase inhibitors (anastrozole or letrozole) in combination with CDK4/6 inhibitor in patients with hormone receptor-positive (HR-positive), human epidermal growth factor receptor 2-negative (HER2-negative) metastatic breast cancer with detectable ESR1 mutation

ipd_sharing_description: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

location_country:
Italy
Austria
United States
Switzerland
Spain
Germany
France
Bulgaria
Japan
Poland
Hungary
Australia
Russian Federation
Portugal
Turkey
Canada
United Kingdom
Korea, Republic of
Taiwan


title: A Descriptive, Prospective, Multi-country, Multicentre Study to Assess Performance of Genital Herpes Simplex Virus-2 (HSV-2) Related Disease Endpoints Based on Patient-reported Health Outcomes, Self-swabbing Collected Via Decentralised Approach in Patients ≥ 18 Years of Age in the United States and Europe.

summary:
The aim of this study is to assess performance of using healthcare tools to understand genital Herpes Simplex Virus-2 (HSV-2) in patients ≥ 18 years of age in the United States and Europe.

More specifically, the study aims to evaluate patient-reported outcome and quality-of-life endpoints as well as the performance study procedures in a decentralised setting. Ultimately, this study will allow generating additional real-world evidence (RWE) on patterns of recurrences and other key parameters.

study_type: Observational

time_perspective: Prospective

location_country:
Italy
Finland
France
Spain
United States
United Kingdom

intervention_type: Procedure


title: Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib

summary: This was an open-label, randomized, dose-finding study in patients with primary or secondary MF (Dynamic International Prognostic Scoring System [DIPSS] risk score of Intermediate-1 to High-Risk) who were previously treated with ruxolitinib. The study was designed to support a pacritinib dosage selection decision with evaluation of 3 dosages.

lead_sponsor: CTI BioPharma

location_country:
Italy
Sweden
France
Hungary
Spain
United States
United Kingdom
Korea, Republic of

location_facility: Imperial College Healthcare NHS Trust - Hammersmith Hospital

location_facility: Istituto Scientifico Romagnolo per lo Studio e la Cura Dei Tumori

location_facility: Oxford University Hospitals NHS Trust - Churchill Hospital

location_facility: Washington University School of Medicine in St. Louis

location_facility: University of Michigan Comprehensive Cancer Center

location_facility: CHU Hopitaux de Bordeaux - Hôpital Haut-Lévêque

location_facility: Guy's and St Thomas' NHS Foundation Trust - Guy's Hospital

location_facility: The University of Chicago Medical Center

location_facility: Centre Hospitalier Regional Universitaire de Lille - Hopital Claude Huriez

location_facility: University of Texas Health Science Center at San Antonio School of Medicine

location_facility: The Catholic University of Korea, Seoul St. Mary's Hospital

location_facility: Northwestern University Feinberg School of Medicine

location_facility: The University of Texas MD Anderson Cancer Center

location_facility: Centre Hospitalier Universitaire de Toulouse- Hôpital Purpan

location_facility: Florida Cancer Specialists & Research Institute

location_facility: UCLA Jonsson Comprehensive Cancer Center

location_facility: The Ohio State University Comprehensive Cancer Center

location_facility: CHU de Nimes - Hopital Universitaire Caremeau

location_facility: Barts Health NHS Trust - The Royal London Hospital


lead_sponsor: Alzheon Inc.

location_country:
France
Spain
United States
United Kingdom
Canada

location_facility: Alzheimer's Research and Treatment Center

location_facility: Hospices Civils de Lyon - Institut du vieillissement

location_facility: Fundacia ACE - Institut Catala de Neurociencies Aplicadas

location_facility: UCSD Shiley-Marcos Alzheimer's Disease Research Center

location_facility: Centro Hospital Universitario Dr. Preset

location_facility: CHU De Montpellier - Hôpital Gui De Chauliac

location_facility: CHU Toulouse - Centre de Recherche Clinique du Gérontopôle

location_facility: Rhode Island Mood & Memory Research Institute

location_facility: Wake Research - Clinical Research Center of Nevada

location_facility: McGill University Research Centre for Studies in Aging

location_facility: CHU de Bordeaux - Groupe Hospitalier Pellegrin

location_facility: Centre Hospitalier Universitaire de Rouen

location_facility: Groupe Hospitalier Saint-Louis, Lariboisière, Fernand Widal

location_facility: Centre Mémoire de Ressources et de Recherche (CM2R) des Hôpitaux Universitaires de Strasbourg

location_facility: Kline Institute for Psychiatric Research

title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety and Biomarker Effects of ALZ-801 in Subjects With Early Alzheimer's Disease and APOE4/4 Genotype

summary: This study is being conducted to evaluate the safety and efficacy of ALZ-801 in Early Alzheimer's disease (AD) subjects with the APOE4/4 genotype. This is a double-blind, randomized trial with one dose of ALZ-801 compared to placebo.


title: A Phase 2, Multicenter, Randomized Study to Compare the Efficacy and Safety of MK-7684A or MK-7684A Plus Docetaxel Versus Docetaxel Monotherapy in the Treatment of Participants With Metastatic Non-small Cell Lung Cancer With Progressive Disease After Treatment With a Platinum Doublet Chemotherapy and Immunotherapy

summary: The main purpose of this study is to compare pembrolizumab/vibostolimab coformulation (MK-7684A) plus docetaxel or pembrolizumab/vibostolimab coformulation to normal saline placebo plus docetaxel. Participants with metastatic non-small cell lung cancer (NSCLC) and progressive disease (PD) after platinum doublet chemotherapy and treatment with one prior anti- programmed cell death 1 (PD-1)/ programmed cell death ligand 1(PD-L1) monoclonal antibody (mAb). MK-7684A is a coformulation product of pembrolizumab/vibostolimab. The dual primary hypotheses of the study are pembrolizumab/vibostolimab coformulation plus docetaxel and pembrolizumab/vibostolimab coformulation is superior to normal saline placebo plus docetaxel with respect to progression free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by blinded independent central review (BICR).

location_country:
Italy
Austria
Switzerland
Spain
Germany
Finland
France
Malaysia
Poland
Israel
Thailand
Argentina
Australia
Belgium
Russian Federation
Denmark
United States
Korea, Republic of
Taiwan

location_facility: Fundación CORI para la Investigación y Prevención del Cáncer ( Site 0005)

location_facility: Ospedale Regionale Bellinzona e Valli ( Site 2203)

location_facility: Saint Petersburg State University-Clinic of advanced medical technologies n. a. Nicolay I. Pirogov (

location_facility: Instituto de Investigaciones Clínicas Mar del Plata ( Site 0002)

location_facility: Azienda Ospedaliera Dei Colli-U.O.C Pneumologia Oncologica DH PNL ONC ( Site 1308)

location_facility: Institut Bergonié - Centre Régional de Lutte Contre Le Cance-Medical Oncology ( Site 1009)

location_facility: N.N.Petrov Research Institute of Oncology-Department of Chemotherapy and Innovative Technologies ( S

location_facility: Taichung Veterans General Hospital-Chest ( Site 2307)

location_facility: Klinik Floridsdorf-Abteilung für Innere Medizin und Pneumologie ( Site 0204)

location_facility: The Catholic University Of Korea St. Vincent's Hospital-Medical Oncology ( Site 2005)

location_facility: Shaare Zedek Medical Center-Oncology ( Site 1206)

location_facility: Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworow Pluca i Klatki Pier

location_facility: Jessa Ziekenhuis-Pulmonology & Thoracic Oncology ( Site 0338)

location_facility: Oulun yliopistollinen sairaala ( Site 0902)

location_facility: Centre Hospitalier Universitaire de Caen - Hôpital Côte de Nacre ( Site 1006)

location_facility: HOSPITAL CLÍNIC DE BARCELONA-ICHMO- Clinic Institut of Haematological and Oncological diseases ( Sit

location_facility: Hospital Universitario Virgen de Valme-Departamento de Oncologia ( Site 2103)

location_facility: Istituto Europeo di Oncologia IRCCS-Divisione di Oncologia Toracica ( Site 1301)

location_facility: Odense Universitetshospital ( Site 0700)

location_facility: Tampereen yliopistollinen sairaala-Oncology ( Site 0906)

location_facility: Saint-Petersburg City Clinical Oncology Dispensary-Department of chemotherapy ( Site 1911)

location_facility: Moscow Clinical Research Center-Chemotherapy department ( Site 1910)

location_facility: HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑON-ONCOLOGY ( Site 2101)

location_facility: Azienda Ospedaliera Universitaria Careggi-SOD ONCOLOGIA MEDICA ( Site 1306)

location_facility: Seoul National University Bundang Hospital ( Site 2003)

location_facility: Ordensklinikum Linz GmbH Elisabethinen-Department of Pneumology ( Site 0203)

location_facility: Turku University Hospital-The Department of Pulmonary Medicine ( Site 0905)

location_facility: Chungbuk National University Hospital-Internal medicine ( Site 2004)

location_facility: Fiona Stanley Hospital-Medical Oncology ( Site 0102)

location_facility: Hattiesburg Clinic Hematology/Oncology ( Site 2511)

location_facility: Budgetary Healthcare Institution of Omsk Region Clinical Oncology Dispensary ( Site 1908)

location_facility: Instituto de Oncología de Rosario ( Site 0003)

location_facility: University of Cincinnati Medical Center-University of Cincinnati Cancer Center ( Site 2526)

location_facility: GBUZ LOKB-Oncology department #1 ( Site 1905)

location_facility: Chang Gung Memorial Hospital at Kaohsiung ( Site 2303)

location_facility: Baptist Health Lexington-Research ( Site 2502)

location_facility: Faculty of Medicine Siriraj Hospital ( Site 2400)

location_facility: Hospital de la Santa Creu i Sant Pau-Oncología Médica ( Site 2102)

location_facility: Azienda Sanitaria Ospedaliera S Luigi Gonzaga-Oncologia Polmonare ( Site 1300)

location_facility: Hospital Tengku Ampuan Afzan ( Site 1500)

location_facility: Nizhegorodsky Regional Oncology Dispensary, Branch #2-chemotherapy ( Site 1909)

location_facility: Mercy Research - David C. Pratt Cancer Center ( Site 2532)

location_facility: Centro de Oncología e Investigación de Buenos Aires ( Site 0008)

location_facility: Gold Coast University Hospital-Clinical Trials Service ( Site 0106)

location_facility: Asan Medical Center-Oncology ( Site 2000)

location_facility: Hospital Privado Universitario de Córdoba ( Site 0001)

location_facility: Grand Hôpital de Charleroi-Oncology & Hematology ( Site 0337)

location_facility: Medizinische Universität Graz ( Site 0201)

location_facility: Centre Hospitalier d'Avignon-Service d'Oncologie médicale et d'hématologie clinique ( Site 1004)

location_facility: Hadassah Medical-Oncology department ( Site 1912)

location_facility: University Malaya Medical Centre ( Site 1501)

location_facility: NATIONAL CHENG-KUNG UNI. HOSP.-clinical trial center ( Site 2302)

location_facility: Fondazione Policlinico Universitario Agostino Gemelli-Medical Oncology ( Site 1303)

location_facility: Central Clinical Hospital of the Presidential Administrative Department ( Site 1902)

location_facility: Mercy Research - Cancer and Hematology Center ( Site 2535)

location_facility: Montefiore- Einstein Center for Cancer Care-Oncology ( Site 2509)

location_facility: Mackay Memorial Hospital-Chest Medicine ( Site 2305)

location_facility: CHU de Toulouse - Hopital Larrey-service de pneumologie ( Site 1008)

location_facility: Rambam Health Care Campus-Oncology ( Site 1203)

location_facility: Ospedale San Raffaele-Oncologia Medica ( Site 1305)

location_facility: St Francis Cancer Center-Research Office ( Site 2531)

location_facility: Hospital Privado de Comunidad ( Site 0004)

location_facility: AZ Sint-Maarten, Campus Leopoldstraat 2 ( Site 0333)


title: A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody®-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma

summary: A phase 1b/2, open-label, multinational, interventional trial to evaluate the safety, tolerability, PK, pharmacodynamics/biomarkers, immunogenicity, and preliminary efficacy of epcoritamab in combination with other standard of care (SOC) agents in subjects with B-NHL.

lead_sponsor: Genmab

location_country:
Italy
Sweden
Netherlands
Finland
France
Czechia
Norway
Belgium
Australia
Spain
Denmark
United States
United Kingdom

location_facility: University of Michigan Comprehensive Cancer Center

location_facility: UMPC Hillman Cancer Center Cancer Pavillion

location_facility: Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII (Presidio Papa Giovanni XXIII)

location_facility: Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico

location_facility: Istituto Scientifico Romagnolo Per Lo Studio e La Cura Dei Tumori

location_facility: Fondazione del Piemonte per l Oncologia Istituto di Candiolo IRCCS

location_facility: Universitair Medisch Centrum Groningen (UMCG)

location_facility: Oslo Universitetssykehus HF, Radiumhospitalet

location_facility: Hospital Universitario Fundacion Jimenez Diaz

location_facility: John Theurer Cancer Center at Hackensack UMC


title: A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating The Efficacy and Safety of AB928 Based Treatment Combinations in Patients With Metastatic Colorectal Cancer

summary: This randomized phase 1b/2 open-label study will evaluate the antitumour activity and safety of etrumadenant (AB928) treatment combinations in participants with metastatic colorectal cancer.

ipd_sharing_description: Arcus will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions.

lead_sponsor: Arcus Biosciences, Inc.

location_country:
Italy
United States
France
Spain
Germany
United Kingdom
Korea, Republic of

location_facility: City of Hope Comprehensive Cancer Center

location_facility: Universitaeres Krebszentrum Leipzig (UCCL)-Universitatsklinikum Leipzig AoR

location_facility: Winship Cancer Institute at Emory University

location_facility: Charite - Universitatsmedizin Berlin - Campus Benjamin Franklin

location_facility: Staedtisches Klinikum Muenchen Bogenhausen

location_facility: IRCCS - Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis

location_facility: Groupe Hospitalier Pitie-Salpetriere-Centre De Recherche et de Medecine de l'Obesite

location_facility: Washington University School of Medicine

location_facility: Klinikum Grosshadern-Klinikum Der Ludwig-Maximilian Universitaet Muenchen

location_facility: NYU Langone Medical Center - NYU Medical Oncology Associates

location_facility: University of Wisconsin School of Medicine

location_facility: Universita di Siena - Azienda Ospedaliera Universitaria Senese-Policlincio Santa Maria Alle Scotte

location_facility: University of Alabama at Birmingham Comprehensive Cancer Center

location_facility: The University of Texas MD Anderson Cancer Center

location_facility: Asan Medical Center, University of Ulsan College of Medicine

location_facility: Hospital General Universitario Gregorio Maranon

location_facility: American Oncology Partners of Maryland,PA

location_facility: Institut Bergonie - Centre Regional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest

location_facility: Hospital Universitario Marques De Valdecilla

location_facility: Seoul National University Hospital (SNUH)

location_facility: Chonnam National University Hwasun Hospital

location_facility: New York-Presbyterian Hospital-Columbia University Medical Center

location_facility: Uniklinik RWTH Aachen Medizinische Klinik III

location_facility: Azienda Ospedaliero Universitaria Careggi-S.O.D. Patologia Medica

location_facility: University of Pennsylvania - Perelman Center for Advanced Medicine - Penn Radiation Oncology

location_facility: Krankenhaus Nordwest GmbH - Institut Fuer Klinisch-Onkologische Forschung (IKF)

location_facility: Ircc Istituto Per La Ricerca E La Cura Del Cancro Di Candiolo Oncologia Medica